Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 49% ± 18% | |
peripheral blood | 20 studies | 57% ± 17% | |
intestine | 14 studies | 42% ± 22% | |
kidney | 8 studies | 38% ± 21% | |
lymph node | 7 studies | 48% ± 20% | |
uterus | 6 studies | 70% ± 14% | |
liver | 6 studies | 43% ± 18% | |
pancreas | 5 studies | 32% ± 8% | |
bone marrow | 5 studies | 32% ± 15% | |
placenta | 5 studies | 39% ± 13% | |
prostate | 5 studies | 51% ± 24% | |
brain | 5 studies | 35% ± 13% | |
eye | 4 studies | 29% ± 15% | |
esophagus | 4 studies | 45% ± 16% | |
skin | 4 studies | 73% ± 14% | |
breast | 4 studies | 68% ± 6% | |
ovary | 3 studies | 45% ± 8% | |
heart | 3 studies | 20% ± 4% | |
adipose | 3 studies | 40% ± 18% | |
adrenal gland | 3 studies | 47% ± 10% | |
stomach | 3 studies | 26% ± 9% | |
thymus | 3 studies | 34% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 10626.25 | 1445 / 1445 | 100% | 227.48 | 183 / 183 |
lung | 100% | 28146.73 | 577 / 578 | 100% | 280.68 | 1155 / 1155 |
ovary | 100% | 15078.12 | 180 / 180 | 100% | 196.68 | 429 / 430 |
uterus | 100% | 8431.72 | 170 / 170 | 100% | 242.05 | 457 / 459 |
breast | 100% | 13368.60 | 459 / 459 | 100% | 190.30 | 1113 / 1118 |
bladder | 100% | 9459.19 | 21 / 21 | 99% | 218.05 | 501 / 504 |
prostate | 100% | 8883.53 | 244 / 245 | 100% | 169.37 | 501 / 502 |
intestine | 100% | 9644.33 | 966 / 966 | 99% | 130.51 | 523 / 527 |
thymus | 100% | 9148.34 | 651 / 653 | 100% | 175.06 | 602 / 605 |
liver | 100% | 7344.85 | 226 / 226 | 99% | 152.79 | 401 / 406 |
adrenal gland | 100% | 12141.15 | 258 / 258 | 98% | 151.34 | 226 / 230 |
stomach | 99% | 7938.70 | 356 / 359 | 99% | 139.20 | 283 / 286 |
kidney | 99% | 7130.35 | 88 / 89 | 98% | 198.53 | 881 / 901 |
pancreas | 88% | 4388.68 | 290 / 328 | 99% | 195.34 | 176 / 178 |
skin | 98% | 13544.49 | 1771 / 1809 | 88% | 83.73 | 416 / 472 |
brain | 71% | 2638.98 | 1867 / 2642 | 100% | 204.84 | 703 / 705 |
blood vessel | 100% | 11208.70 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 349.33 | 29 / 29 |
spleen | 100% | 17425.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 317.98 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 86.55 | 1 / 1 |
adipose | 100% | 17343.61 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 6355.26 | 825 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 10954.89 | 866 / 929 | 0% | 0 | 0 / 0 |
muscle | 91% | 5797.82 | 727 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 26% | 13.40 | 21 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031663 | Biological process | lipopolysaccharide-mediated signaling pathway |
GO_0045638 | Biological process | negative regulation of myeloid cell differentiation |
GO_0035994 | Biological process | response to muscle stretch |
GO_0070427 | Biological process | nucleotide-binding oligomerization domain containing 1 signaling pathway |
GO_0051247 | Biological process | positive regulation of protein metabolic process |
GO_0007219 | Biological process | Notch signaling pathway |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0032495 | Biological process | response to muramyl dipeptide |
GO_0043330 | Biological process | response to exogenous dsRNA |
GO_0050853 | Biological process | B cell receptor signaling pathway |
GO_0070498 | Biological process | interleukin-1-mediated signaling pathway |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_0070417 | Biological process | cellular response to cold |
GO_0010745 | Biological process | negative regulation of macrophage derived foam cell differentiation |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0060261 | Biological process | positive regulation of transcription initiation by RNA polymerase II |
GO_0007253 | Biological process | cytoplasmic sequestering of NF-kappaB |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0010875 | Biological process | positive regulation of cholesterol efflux |
GO_0006606 | Biological process | protein import into nucleus |
GO_0034142 | Biological process | toll-like receptor 4 signaling pathway |
GO_0070431 | Biological process | nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0010888 | Biological process | negative regulation of lipid storage |
GO_0045746 | Biological process | negative regulation of Notch signaling pathway |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005886 | Cellular component | plasma membrane |
GO_0033256 | Cellular component | I-kappaB/NF-kappaB complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0008139 | Molecular function | nuclear localization sequence binding |
GO_0140416 | Molecular function | transcription regulator inhibitor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0140311 | Molecular function | protein sequestering activity |
GO_0140313 | Molecular function | molecular sequestering activity |
GO_0005515 | Molecular function | protein binding |
GO_0051059 | Molecular function | NF-kappaB binding |
Gene name | NFKBIA |
Protein name | NFKB inhibitor alpha NF-kappa-B inhibitor alpha (I-kappa-B-alpha) (IkB-alpha) (IkappaBalpha) (Major histocompatibility complex enhancer-binding protein MAD3) NF-kappa-B inhibitor alpha (I-kappa-B-alpha) |
Synonyms | MAD3 NFKBI IKBA |
Description | FUNCTION: Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals . On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription . . |
Accessions | G3V286 P25963 G3V3I4 ENST00000553342.2 ENST00000697962.1 ENST00000557389.1 A0A8V8TLC3 G3V3K1 A0A8V8TLE7 G3V2A2 ENST00000216797.10 ENST00000697961.1 ENST00000554001.5 ENST00000557140.5 |